

ANNOUNCING THE APPROVAL OF FUZEON™ AND THE FUZEON PROGRESSIVE DISTRIBUTION PROGRAM

Roche and Trimeris are pleased to announce the recent approval of FUZEON (enfuvirtide) by the US Food and Drug Administration (FDA) and details of the FUZEON Progressive Distribution Program. The FUZEON Progressive Distribution Program is designed to make FUZEON available to as many patients as possible and to ensure uninterrupted access to the drug during a potential period of limited supply.

FUZEON, requiring more than 100 steps in its production process, is one of the most challenging and complex molecules ever chemically manufactured at commercial scale. FUZEON'S complex manufacturing process and the anticipated limited supply have prompted the decision to allocate a safety supply of FUZEON for patients who initiate therapy to help ensure continuous treatment. Roche and Trimeris anticipate being able to provide FUZEON progressively through the year, expanding the available supply in 2004 and beyond.

To maximize patient access to FUZEON and manage the supply efficiently while it is limited, the FUZEON Progressive Distribution Program will serve as a single point of access for FUZEON. Allocation of FUZEON will be made on a first-come, first-served basis. The FUZEON Progressive Distribution Program can receive prescriptions from physicians via fax and will ship FUZEON to the patient's or the prescribing physician's delivery point of choice. To enroll a patient in the FUZEON Progressive Distribution Program, simply complete the attached patient enrollment form and fax it to 1-877-428-9520.*

For your convenience, you will also find a general overview of the FUZEON Progressive Distribution Program included with this letter.

Physicians interested in prescribing FUZEON for their patients or who would like more information about FUZEON or the FUZEON Progressive Distribution Program can call 1-866-694-6670 or visit www.FUZEON.com. If you have any additional questions, please contact your FUZEON Sales Specialist.

** For information about obtaining FUZEON for patients cared for in the Department of Veterans Affairs/VA medical system, please see <http://vawww.vhaco.va.gov/phshcg/> or contact your VA facility's clinician or coordinator.*

If you wish to have your fax number removed from the AMA's Physician Fax Database call 1-800-621-8335.

16-004-118-009-0503



Trimeris, Inc.
4727 University Drive
Durham, North Carolina 27707
www.trimeris.com



Pharmaceuticals

Roche Laboratories Inc.
340 Kingsland Street
Nutley, New Jersey 07110-1199
www.rocheusa.com